Asset 1
Indications

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy ... Read More 

Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission

Relapsed or refractory disease

Important Safety Information Prescribing Information Medication Guide Indications Patient Site Connect with a BLINCYTO® rep

You are now leaving BLINCYTOHCP.com

The content of the linked site is the sole responsibility of the site provider. Amgen Inc. does not control or endorse this third-party website.

Go back to Blincytohcp.com
External Page

NOW AVAILABLEBLINCYTO® offers 72- and 96-hour* infusion durations—offering more flexibility for you and your patients

The choice between these infusion duration options should be made by the treating healthcare professional, considering the frequency of the infusion bag changes and the weight of the patient.†

*Prepared with Bacteriostatic 0.9% Sodium Chloride Injection (containing 0.9% benzyl alcohol).

†Use the preservative-free preparations of BLINCYTO® where possible in neonates. When prescribing BLINCYTO® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO® (with preservative), other products containing benzyl alcohol or other excipients (eg, ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway. Serious adverse reactions, including fatal reactions and the “gasping syndrome,” have been reported in very low birth weight neonates born weighing less than 1500 g, and early preterm neonates who received intravenous drugs containing benzyl alcohol as a preservative.

Please see Indications in above "Indications" tray and full Important Safety Information, including BOXED WARNINGS, below.

Reference: BLINCYTO® (blinatumomab) prescribing information, Amgen.

BLINCYTO® (blinatumomab) logo

Frontline Consolidation: The E1910 study

Study design: A multinational, randomized, controlled, phase 3 trial of BLINCYTO® alternating with chemotherapy vs chemotherapy alone in frontline consolidation in 224 newly diagnosed patients aged 30–70 years with Ph(–) B-cell precursor ALL. OS was calculated from time of randomization until death due to any cause.1,2 Median RFS in E1910 was not reached in the BLINCYTO® arm (n=112) vs 22.4 months in the chemotherapy only arm (n=112); HR: 0.46 (95% CI: 0.27–0.78); P = 0.004. Median follow-up was 3.6 years in both arms.2,3

In patients who are MRD(–), integrate BLINCYTO® into frontline consolidation across ages* for improved overall survival vs chemotherapy alone1,2

E1910 study infographic comparing overall survival; BLINCYTO® showed higher OS rates than chemotherapy across all age groups
E1910 study infographic comparing overall survival; BLINCYTO® showed higher OS rates than chemotherapy across all age groups
  • Median RFS in E1910 was not reached in the BLINCYTO® arm (n=112) vs 22.4 months in the chemotherapy only arm (n=112); HR: 0.46 (95% CI: 0.27–0.78); P = 0.004. Median follow-up was 3.6 years in both arms2,4

*Indicated for adult and pediatric patients 1 month and older.1

†Based on KM estimates. Median follow-up was 4.5 years.5

‡Study met its primary endpoint.1

§The hazard ratio estimates are obtained from a stratified Cox regression model at the third interim analysis. Median follow-up was 3.6 years in both arms.1

**Stratified log-rank test.1

††Age < or ≥ 55 years old was a prespecified stratification factor in the E1910 study, while the analysis of patients 30–39 years old was post-hoc. Efficacy in the 30–39 year old subgroup was not a study objective and the study was not powered to assess for an OS benefit in this subgroup.2

ALL, acute lymphoblastic leukemia; CI, confidence interval; HR, hazard ratio; KM, Kaplan-Meier; MRD, measurable or minimal residual disease; OS, overall survival; Ph(–), Philadelphia chromosome–negative; RFS, relapse-free survival.

In patients who were MRD(–) 5-year OS was 82.4% in the BLINCYTO® arm vs 62.5% in the chemotherapy only arm1,2

  • Primary endpoint was OS, 3-year KM estimates: 84.8% in the BLINCYTO® arm (n=112) vs 69.0% in the chemotherapy only arm (n=112); HR 0.42 (95% CI: 0.24–0.75);* P = 0.003 (the stratified log-rank test)1
  • Adding BLINCYTO® to frontline consolidation reduced the risk of death from any cause by 58% vs chemotherapy alone in patients who were MRD(–)1

OS in patients who were MRD(–)1,5

javascript:void();
e1910-os-mrd
  • In a later analysis (see KM curve above), median follow-up was 4.5 years in both the BLINCYTO® and chemotherapy only arms1
  • MRD was assessed centrally using standardized 6-color flow cytometry, with MRD(–) defined as < 0.01% leukemic cells in the bone marrow.2 The MRD tests were performed at laboratory sites using assays that have not been analytically validated by FDA‡

*The hazard ratio estimates are obtained from a stratified Cox regression model at the third interim analysis. Median follow-up was 3.6 years in both arms. OS was calculated from time of randomization until death due to any cause.1

†Based on KM estimates.5

‡Per FDA, the process of analytical validation is defined as establishing that the performance characteristics of the assays are acceptable in terms of its accuracy, precision, and other relevant analytical performance characteristics using a specified technical protocol, including specimen collection, handling, pre-analytic processing, and storage procedures.6

FDA, Food and Drug Administration.

Numerically greater OS was observed in patients who received 4 cycles vs 1–2 cycles of BLINCYTO® in frontline consolidation7

A post-hoc analysis of OS among patients in the BLINCYTO® arm:
4 cycles of BLINCYTO® vs 1–2 cycles7,*

modal
e1910-post-hoc
  • This was an unplanned landmark analysis of the E1910 study. Efficacy in this subgroup was not a prespecified study objective and the study was not powered to assess efficacy in this subgroup7
  • Patients who came off study or died from treatment-related complications (n=4) prior to 9 months after randomization were excluded from the analysis8
    • Per the E1910 study protocol, patients in the BLINCYTO® arm could go to HSCT after 1–2 cycles of BLINCYTO®1
    • Additional factors related to receiving fewer cycles may be due to experiencing toxicity, disease progression, patient withdrawal, or other complications. These reasons may be potential confounding factors for this analysis. Further studies would be needed to determine if fewer cycles can provide a similar benefit to 4 cycles
  • In the E1910 study, 57% of patients received 4 cycles of BLINCYTO®8

*Time 0 represents 9 months after step 3 randomization (when patients were anticipated to complete 4 cycles of BLINCYTO® treatment).7

HSCT, allogeneic hematopoietic stem cell transplantation.

In a post-hoc analysis of patients aged 30–39 years with MRD negativity 3-year OS was 100% in the BLINCYTO® arm vs 73% in the chemotherapy only arm4

Post-hoc analysis of OS: Patients aged 30–39 years with MRD negativity2,4

modal
e1910-post-hoc-mrd
  • This was a post-hoc analysis of the E1910 study. Efficacy in the 30–39 year old subgroup was not a prespecified study objective and the study was not powered to assess for efficacy in this subgroup2

E1910 study design and baseline characteristics of patients

E1910 study design: A multinational, randomized, controlled, phase 3 trial that compared BLINCYTO® alternating with chemotherapy with chemotherapy alone in frontline consolidation in 224 newly diagnosed patients aged 30–70 years with Ph(–) B-cell precursor ALL.1,2

flowchart outlining chemotherapy steps with BLINCYTO® added based on age and CD20 status

During step 3 randomization in frontline consolidation:1

modal

HSCT:

  • 22 patients in each arm underwent HSCT2

Number of cycles:

  • In the BLINCYTO® arm (n=111), the median number of cycles was 8 (4 cycles of BLINCYTO® and 4 cycles of chemotherapy)1
    • 57% of patients in the E1910 study received 4 cycles of BLINCYTO®8
  • In the chemotherapy only arm (n=112), the median number of cycles was 41

*MRD was assessed centrally using standardized 6-color flow cytometry, with MRD(–) defined as < 0.01% leukemic cells in the bone marrow.2 The MRD tests were performed at laboratory sites using assays that have not been analytically validated by FDA.†

†Per FDA, the process of analytical validation is defined as establishing that the performance characteristics of the assays are acceptable in terms of its accuracy, precision, and other relevant analytical performance characteristics using a specified technical protocol, including specimen collection, handling, pre-analytic processing, and storage procedures.6

orange-blue-background-135orange-blue-background-135-mb

See the post-hoc analysis of using 4 cycles of BLINCYTO®
in frontline consolidation
Key inclusion criteria1,9
Patients aged 30–70 years
Newly diagnosed Ph(–) B-cell precursor ALL
ECOG PS 0–2‡
Key exclusion criteria9
Mature B-cell ALL (Burkitt's-like leukemia)
Receiving treatment for concurrent active malignancy
History or presence of clinically relevant CNS pathology

‡Step 3 (randomization) inclusion criterion.9

Demographics and baseline characteristics1

Characteristic BLINCYTO® +
chemotherapy arm
(n=112) 		Chemotherapy
only arm
(n=112)
Age
Median, years (min, max) 52 (31, 69) 50 (30, 70)
Sex, n (%)
Males 55 (49) 56 (50)
Race, n (%)
American Indian or Alaska Native 2 (2) 1 (1)
Asian 3 (3) 2 (2)
Black (or African American) 9 (8) 4 (4)
Native Hawaiian or Other Pacific Islander 1 (1) 0
White 87 (78) 89 (79)
Not reported 5 (4) 6 (5)
Unknown 5 (4) 10 (9)
Ethnicity, n (%)
Hispanic or Latino 13 (12) 10 (9)
Not Hispanic or Latino 95 (85) 95 (85)
Not reported 1 (1) 2 (2)
Unknown 3 (3) 5 (4)
Stratification Factors, n (%)
Age < 55 years at randomization 65 (58) 65 (58)
CD20-positive 45 (40) 46 (41)
Rituximab use 33 (29) 36 (32)
Planned HSCT 36 (32) 35 (31)

BFM, Berlin-Frankfurt-Münster; CD, cluster of differentiation; cIV, continuous intravenous; CNS, central nervous system; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; ECOG PS, Eastern Cooperative Oncology Group performance score; POMP, 6-Mercaptopurine, vincristine, methotrexate, prednisone.

Blinatumomab is recommended by the National Comprehensive Cancer Network® (NCCN®) as a preferred therapy as part of frontline consolidation for AYA and adult patients with MRD(+) or MRD(–) Ph(–) B-cell precursor ALL10

NCCN Recommended

Adverse reactions with a difference between arms of ≥ 10% for any Grade or ≥ 5% for Grade 3 or 4 during consolidation1

Adverse reaction BLINCYTO® +
chemotherapy arm
(n=111) 		Chemotherapy only arm
(n=112)
All Grades
(%)‡‡		 Grade 3 or 4
(%)		 All Grades
(%)		 Grade 3 or 4
(%)
Blood and lymphatic system disorders
Neutropenia* 82 77 89 89
Thrombocytopenia* 75 57 75 71
Anemia 59 29 50 38
Leukopenia* 43 41 57 56
Lymphopenia* 32 30 25 23
Febrile neutropenia 19 19 25 25
Gastrointestinal disorders
Nausea† 32 5 22 4
Diarrhea* 29 3 15 3
Immune system disorders
Cytokine release syndrome (CRS)‡ 16 4 0 0
Infections and infestations
Infections — pathogen unspecified 35 31 22 21
Musculoskeletal and connective tissue disorders
Musculoskeletal pain§ 23 5 5 4
Nervous system disorders
Headache** 41 5 30 5
Tremor** 23 3 3 0
Aphasia**,†† 10 8 0 0
Vascular disorders
Hypertension 12 10 5 3
  • Fatal adverse reactions occurred in 2% (n=2/111) of patients during BLINCYTO® cycles and were due to infection (n=1) and coagulopathy (n=1)1
  • Permanent discontinuation of BLINCYTO® due to an adverse reaction occurred in 2% of patients. Dosage interruptions of BLINCYTO® due to an adverse reaction occurred in 5% of patients. Dose reductions of BLINCYTO® due to an adverse reaction occurred in 28% of patients1
  • The rate of Grade 3 or 4 CRS events was 4% when BLINCYTO® was used in frontline consolidation1
  • The most common (≥ 20%) adverse reactions during consolidation cycles in the BLINCYTO® arm were neutropenia, thrombocytopenia, anemia, leukopenia, headache, infection, nausea, lymphopenia, diarrhea, musculoskeletal pain, and tremor1

*Other related adverse reactions included:1

†Nausea: vomiting.1

‡CRS: capillary leak syndrome.1

§Musculoskeletal pain: pain in extremity, back pain, arthralgia, myalgia, neck pain, flank pain, bone pain, non-cardiac chest pain.1

**May represent ICANS.1

††Aphasia: dysarthria.1

‡‡Includes the following fatal adverse reaction: infection (n=1).1

AYA, adolescent and young adult; ICANS, immune effector cell-associated neurotoxicity syndrome.

See more

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

  • Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.
  • Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.
Contraindications

BLINCYTO® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.

Warnings and Precautions
  • Cytokine Release Syndrome (CRS): CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin, and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO®, CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO® until CRS resolves. Discontinue BLINCYTO® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS.
  • Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome:
    BLINCYTO® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO®, but some resulted in treatment discontinuation.

    The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome may have a higher risk of seizures with BLINCYTO® therapy; consider seizure prophylaxis prior to initiation of BLINCYTO® for these patients.

    Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO® and/or treat with corticosteroids as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities.

  • Infections: Approximately 25% of patients receiving BLINCYTO® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO® as needed.
  • Tumor Lysis Syndrome (TLS), which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used during BLINCYTO® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO® as needed to manage these events.
  • Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO® infusion and interrupt BLINCYTO® if prolonged neutropenia occurs.
  • Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO® is being administered.
  • Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO®, although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO® treatment. BLINCYTO® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN.
  • Pancreatitis: Fatal pancreatitis has been reported in patients receiving BLINCYTO® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO® and dexamethasone as needed.
  • Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO®, especially in patients previously treated with cranial irradiation and antileukemic chemotherapy.
  • Preparation and administration errors have occurred with BLINCYTO® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose).
  • Immunization: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO®.
  • Benzyl Alcohol Toxicity in Neonates: Serious adverse reactions, including fatal reactions and the “gasping syndrome,” have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol.

    Use the preservative-free preparations of BLINCYTO® where possible in neonates. When prescribing BLINCYTO® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway.

    Monitor neonatal patients receiving BLINCYTO® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO® 72-Hour bag (with preservative) and 96-Hour bag (with preservative) contain 2.5 mg of benzyl alcohol per mL, and the 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL.

  • Embryo-Fetal Toxicity: Based on its mechanism of action, BLINCYTO® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO® and for 48 hours after the last dose.
Adverse Reactions
  • The safety of BLINCYTO® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B-cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.
Dosage and Administration Guidelines
  • BLINCYTO® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm.
  • It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose).
INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

  • Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
  • Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
  • Relapsed or refractory disease

Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS.

BLINCYTO® is a registered trademark of Amgen Inc.

See more

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

  • Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.
  • Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.
Contraindications

References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320-333. 3. Litzow MR, Sun Z, Paietta E, et al. ECOG-ACRIN-E1910 NCTN clinical trial: A phase III randomized trial of blinatumomab for newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults. Presented at: 64th ASH Annual Meeting and Exposition; December 10–13, 2022; New Orleans, LA. 4. Dinner SN, Sun Z, Paietta EM, et al. Addition of blinatumomab to consolidation therapy for younger adults (< 55 years) with newly diagnosed BCR:ABL1-negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial. Presented at: 30th European Haematology Association Congress; June 12–15, 2025; Milan, Italy. Abstract S110. 5. Data on file, Amgen; [1]; 2024. 6. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. https://www.fda.gov/files/drugs/published/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf. Accessed August 4, 2025. 7. Data on file, Amgen; [2]; 2024. 8. Luger SM, Sun Z, Mattison RJ, et al. Assessment of outcomes of consolidation therapy by number of cycles of blinatumomab received in newly diagnosed measurable residual disease negative patients with B-lineage acute lymphoblastic leukemia: in the ECOG-ACRIN E1910 randomized phase III National Clinical Trials Network Trial. Poster presented at: 65th ASH Annual Meeting and Exposition; December 9–12, 2023; San Diego, CA. Abstract 2877. 9. ClinicalTrials.gov. Combination chemotherapy with or without blinatumomab in treating patients with newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia. https://clinicaltrials.gov/study/NCT02003222. Accessed August 11, 2025. 10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

BACK TO TOP